8-K: ImmunityBio's ANKTIVA Gains UAE Approval for Bladder & Lung Cancer

ImmunityBio announced that the UAE has granted marketing authorization for ANKTIVA in two indications: BCG-unresponsive bladder cancer and metastatic non-small cell lung cancer.

Summary

• ImmunityBio, Inc. has received marketing authorization from the Emirates Drug Establishment (EDE) in the United Arab Emirates (UAE) for its drug ANKTIVA.
• The authorization covers two distinct indications: ANKTIVA in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), and ANKTIVA in combination with immune checkpoint inhibitors for metastatic non-small cell lung cancer (NSCLC).
• This approval marks the broadest to date for ANKTIVA, being the first worldwide to cover the full spectrum of BCG-unresponsive NMIBC, including carcinoma in situ (CIS) with or without papillary tumors, and papillary disease alone.
• For NMIBC, ANKTIVA plus BCG showed a 71% complete response rate in the CIS cohort with responses lasting over 54 months, and an 83% cystectomy-free rate at 36 months in the papillary-only cohort.
• For NSCLC, ANKTIVA plus a checkpoint inhibitor demonstrated a median overall survival of 14.6 months in checkpoint-refractory advanced NSCLC patients.
• The UAE is the fifth regulatory jurisdiction to authorize ANKTIVA, expanding its global reach to 34 countries.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development due to the significant regulatory milestone achieved with the UAE approval for ANKTIVA across two major cancer indications, expanding its global reach.

Positives

• Marketing authorization granted by the Emirates Drug Establishment (EDE) in the UAE for ANKTIVA.
• Approval covers two significant indications: BCG-unresponsive NMIBC and metastatic NSCLC.
• The NMIBC approval is the first globally to encompass the full spectrum of BCG-unresponsive disease (CIS with or without papillary tumors, and papillary disease alone).
• High complete response rate of 71% in NMIBC CIS cohort with ANKTIVA + BCG, with durable responses exceeding 54 months.
• High cystectomy-free rate of 83% at 36 months in NMIBC papillary-only cohort.
• Median overall survival of 14.6 months in NSCLC patients treated with ANKTIVA + checkpoint inhibitor.
• Global regulatory footprint expanded to 34 countries, with the UAE being the fifth regulatory jurisdiction to authorize ANKTIVA.

Negatives

• The filing does not explicitly mention any negative clinical trial results or setbacks.
• Potential for global BCG supply shortages could limit combination therapy availability.
• Reliance on regional partners like Modern Pharmaceutical Company for successful launch and distribution in the UAE.

Risks

• Potential for delayed cystectomy in NMIBC patients to lead to muscle-invasive or metastatic bladder cancer.
• Global BCG supply shortages could impact the availability of combination therapy.
• Reliance on regional partners for successful launch and distribution.
• Timing and outcome of pricing and reimbursement decisions by UAE health authorities.
• Manufacturing and supply chain complexities for international distribution.
• Regulatory actions in any of the 34 countries where ANKTIVA is authorized could affect labeling or market access.
• Competition from existing or new therapies in the UAE and broader Gulf region.

Future Outlook

The company anticipates broadening access across the Gulf region through its partnership with Modern Pharmaceutical Company, leveraging the strength of the same data packages submitted to the FDA for these approvals. Future regulatory submissions and outcomes in the US and other jurisdictions are pending.

Management Comments

• "This approval by the Emirates Drug Establishment is the first in the world to reach across the entire spectrum of non-muscle invasive bladder cancer from carcinoma in situ with or without papillary tumors, and, for the first time, papillary disease alone."
• "That same immunological backbone now extends to lung cancer, where ANKTIVA, by stimulating NK cells which target tumor cells that have lost MHC-I T cell receptors, can restore the immune response in patients whose disease has progressed on checkpoint therapy."
• "With this authorization, the global regulatory footprint for ANKTIVA now includes 34 countries. Securing approvals across two distinct indications, bladder cancer and lung cancer, on the strength of the same data packages we submitted to the FDA, positions us to broaden access across the Gulf region through our partnership with Modern Pharmaceutical Company, in markets where the need for new treatment options is significant."

Industry Context

StockSavvy.ai notes that this UAE approval for ANKTIVA in both bladder and lung cancer signifies a significant step in expanding the drug's global reach and validates its efficacy across different oncology indications. The broadest approval for NMIBC to date addresses a critical unmet need in the market.

Stakeholder Impact

• Shareholders: Positive impact due to regulatory approval and expansion of global market access for a key product.
• Patients: Increased access to a novel immunotherapy treatment option for BCG-unresponsive NMIBC and metastatic NSCLC.
• Healthcare Providers: Availability of a new treatment option for challenging oncological conditions.
• Partners (Modern Pharmaceutical Company): Opportunity to market and distribute ANKTIVA in the UAE and potentially broader Gulf region.

Next Steps

• Broaden access to ANKTIVA across the Gulf region through partnership with Modern Pharmaceutical Company.
• Continue pursuing regulatory submissions and outcomes in the United States and other jurisdictions for ANKTIVA.

Key Dates

Recommendation

While the UAE approval is a positive step, it is a single market authorization. The company's broader US and EU regulatory pathways, particularly for NSCLC, and its financial performance remain key factors for a more definitive recommendation. The expansion to 34 countries is noted, but the impact of this specific authorization on overall revenue is yet to be determined.

Keywords

ANKTIVA, Non-Muscle Invasive Bladder Cancer, Non-Small Cell Lung Cancer, Bladder Cancer, Lung Cancer, Immunotherapy, Oncology, Biotechnology